| # | Title | Journal | Year | Citations |
|---|
| 1 | STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT | Lancet, The | 1986 | 39,917 |
| 2 | Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China | Lancet, The | 2020 | 36,800 |
| 3 | Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study | Lancet, The | 2020 | 21,698 |
| 4 | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) | Lancet, The | 1998 | 18,169 |
| 5 | Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study | Lancet, The | 2020 | 16,090 |
| 6 | Statistical methods for assessing agreement between two methods of clinical measurement | Lancet, The | 1986 | 11,986 |
| 7 | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Lancet, The | 2012 | 11,038 |
| 8 | The psychological impact of quarantine and how to reduce it: rapid review of the evidence | Lancet, The | 2020 | 10,740 |
| 9 | ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS | Lancet, The | 1974 | 10,523 |
| 10 | Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study | Lancet, The | 2004 | 9,716 |
| 11 | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies | Lancet, The | 2007 | 9,433 |
| 12 | Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding | Lancet, The | 2020 | 9,430 |
| 13 | A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 | Lancet, The | 2012 | 9,397 |
| 14 | Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 | Lancet, The | 2014 | 9,122 |
| 15 | Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies | Lancet, The | 2004 | 9,083 |
| 16 | Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | Lancet, The | 2018 | 8,569 |
| 17 | Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies | Lancet, The | 2002 | 8,434 |
| 18 | COVID-19: consider cytokine storm syndromes and immunosuppression | Lancet, The | 2020 | 7,677 |
| 19 | Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 | Lancet, The | 2020 | 7,664 |
| 20 | MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial | Lancet, The | 2002 | 7,542 |
| 21 | Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) | Lancet, The | 1994 | 7,432 |
| 22 | Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) | Lancet, The | 1998 | 7,385 |
| 23 | A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster | Lancet, The | 2020 | 7,120 |
| 24 | Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 | Lancet, The | 2012 | 7,061 |
| 25 | Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Lancet, The | 2005 | 6,840 |
| 26 | The metabolic syndrome—a new worldwide definition | Lancet, The | 2005 | 6,696 |
| 27 | Inflammation and cancer: back to Virchow? | Lancet, The | 2001 | 6,677 |
| 28 | ASSESSMENT OF OUTCOME AFTER SEVERE BRAIN DAMAGE A Practical Scale | Lancet, The | 1975 | 6,557 |
| 29 | Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 | Lancet, The | 2012 | 6,376 |
| 30 | Global burden of hypertension: analysis of worldwide data | Lancet, The | 2005 | 6,235 |
| 31 | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) | Lancet, The | 1996 | 6,209 |
| 32 | Frailty in elderly people | Lancet, The | 2013 | 6,145 |
| 33 | Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins | Lancet, The | 2005 | 6,113 |
| 34 | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Lancet, The | 1998 | 6,110 |
| 35 | Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy | Lancet, The | 2012 | 6,107 |
| 36 | Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study | Lancet, The | 1997 | 5,906 |
| 37 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Lancet, The | 2010 | 5,899 |
| 38 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Lancet, The | 2001 | 5,888 |
| 39 | Epidemiology and causes of preterm birth | Lancet, The | 2008 | 5,851 |
| 40 | Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 | Lancet, The | 2015 | 5,847 |
| 41 | Maternal and child undernutrition and overweight in low-income and middle-income countries | Lancet, The | 2013 | 5,719 |
| 42 | A novel coronavirus outbreak of global health concern | Lancet, The | 2020 | 5,656 |
| 43 | Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 | Lancet, The | 2017 | 5,578 |
| 44 | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Lancet, The | 2016 | 5,456 |
| 45 | Food in the Anthropocene: the EAT–Lancet Commission on healthy diets from sustainable food systems | Lancet, The | 2019 | 5,421 |
| 46 | Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial | Lancet, The | 1998 | 5,398 |
| 47 | Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials | Lancet, The | 2016 | 5,331 |
| 48 | Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 | Lancet, The | 2016 | 5,298 |
| 49 | The metabolic syndrome | Lancet, The | 2005 | 5,212 |
| 50 | Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials | Lancet, The | 2010 | 5,162 |
